PRIME exits and American Healthcare Capital are pleased to introduce an innovative medical equipment developer, manufacturer, and distributor of non-invasive spine care products for sale. The Company’s current flagship product is a patented, FDA-cleared multi-purpose therapeutic device for the treatment of patients suffering from severe low back pain and sciatica due to protruding or herniated intervertebral discs, acute facet problems, and/or degenerative disc disease. This medical device is utilized by Pain Management Centers, Orthopedic Hospitals, Sports Medicine, Physical Therapists, and Chiropractors in over 14 countries.

The Company’s MedTech Device focuses on the alleviation of back pain. The growing prevalence of chronic conditions is one of the key aspects anticipated to contribute to the market\’s growth in Pain Management. The issues of musculoskeletal conditions, such as osteoarthritis, orthopedic degenerative diseases, arthritis, and rheumatoid arthritis, are rising significantly. This has increased the prevalence of chronic pain in these people and the incapability to carry out everyday chores. The CDC expects around 35 million individuals to be limited in their usual activities because of arthritis by 2040. Additionally, the sports and fitness industry in the U.S. is also impacted significantly by lower back pain, as approximately 20% of all injuries involve lower back and neck injuries. Certain sports experience a higher number of back and neck injuries as compared to others. The next generation pain management medical device industry has experienced increased demand in recent years and is expected to continue to grow as the median age of the U.S. population increases.

The company is in the process of developing three next-generation non-invasive spine care products with patents pending, which are intended to significantly impact physical therapy, sports medicine, fitness, and the wellness sectors. The Company’s current flagship medical device is being updated for lower production costs, yielding higher margins and enhanced software. The software will have machine learning (AI) where data points of treatment will be entered and it will automate the next level of treatments. The current version of the MedTech device has been utilized during many sporting events for nearly 5 years by the PGA/USGA for the US OPEN.

The Company has engaged with professional athletes, athletic trainers, physical therapists, and medical doctors of teams involving the NFL, NHL, NBA, MLB, and USTA. The next generation fitness technologies device will improve athletic health and performance, injury recovery, and facilitate injury prevention.

The next generation medical device company is ending its pre-revenue stage and has begun marketing its FDA-cleared therapeutic device. Organizational infrastructure is being built out and managed along with a domestic and international sales pipeline for growth. The sales of its current device are “proof of concept” for the development and launch of the Next Generation of products. The market segments and channels of distribution are very wide, with expected coverage in hospitals, clinics, physical therapy settings, and all areas of sports and fitness, as well as high-traffic areas of malls and airports. Within 3 years the Company is forecasting to generate $100 million in Revenues at a 38% EBITDA margin.

The Company is seeking $10 million of growth capital for the development and launch of 3 next generation products.

The company is looking for a strategic or equity buyer who can help implement its brand into the global markets by taking advantage of the enormous upside potential in the pain management devices market. Therefore, the Owners will consider either growth funding of $10 million or a majority equity investment while remaining with the Company to implement the growth opportunities. Price Is to Be Determined with or without an Earnout Going Forward.